AC
CNTA

Aaron Cowen’s Centessa Pharmaceuticals CNTA Stock Holding History

Aaron Cowen’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-70,000
Closed -$1.12M – 100
2024
Q3 		$1.12M Buy
+70,000
New +$858K 0.04% 85

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Aaron Cowen's CNTA Position: Q4 2024 in Review

Aaron Cowen sold out of Centessa Pharmaceuticals (CNTA) in Q4 2024, closing a stake of 70,000 shares — an estimated $1.12M sold.

Aaron Cowen first reported a position in CNTA in Q3 2024 and held it in 1 quarter. The position peaked at $1.12M in Q3 2024. 114 funds tracked by Wall St. Rank hold CNTA as of Q4 2024.

  • Aaron Cowen reported no remaining Centessa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Aaron Cowen sold 70,000 Centessa Pharmaceuticals shares in Q4 2024, an estimated $1.12M.
  • Aaron Cowen first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Aaron Cowen's Centessa Pharmaceuticals position peaked at $1.12M in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2024.

Based on Suvretta Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.